리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 08월
페이지 정보:영문 282 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 사이버나이프 시장은 2030년까지 17억 달러에 달할 전망
2024년에 6억 1,840만 달러로 추정되는 세계의 사이버나이프 시장은 2024-2030년의 분석 기간에 CAGR 18.5%로 성장하며, 2030년에는 17억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 암 애플리케이션은 CAGR 20.0%를 기록하며, 분석 기간 종료까지 11억 달러에 달할 것으로 예측됩니다. 종양 애플리케이션 분야의 성장률은 분석 기간 중 CAGR 17.3%로 추정됩니다.
미국 시장은 1억 6,850만 달러로 추정, 중국은 CAGR 24.5%로 성장 예측
미국의 사이버나이프 시장은 2024년에 1억 6,850만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR을 24.5%로, 2030년까지 3억 8,750만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 각각 분석 기간 중 13.6%와 16.8%의 CAGR로 성장할 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 14.8%로 성장할 것으로 예측됩니다.
세계의 사이버나이프 시장 - 주요 동향과 시장 성장 촉진요인 정리
사이버나이프가 정밀 방사선 치료에서 인정받는 이유는?
최첨단 로봇 방사선 수술 시스템인 사이버나이프는 비침습적이고 정밀한 방사선 치료를 제공함으로써 암 치료에 혁명을 일으켰습니다. 기존 방사선 기술과 달리 사이버나이프는 실시간 영상 안내와 로봇 기술을 활용해 밀리미터 이하의 정밀도로 종양을 조준하고 주변 건강한 조직의 손상을 최소화합니다. 이를 통해 뇌종양, 전립선암, 폐암, 척추암, 췌장암 등 복잡한 암 치료에 필수적인 툴이 되고 있습니다.
세계에서 암 발병률이 증가함에 따라 첨단 방사선 치료 솔루션에 대한 수요가 증가하고 있으며, 사이버나이프는 통증이 없는 외래 치료를 원하는 환자들에게 선호되는 치료법으로 부상하고 있습니다. 사이버나이프는 특히 폐암, 전립선암 등 환자의 움직임에 적응할 수 있으며, 치료 효과와 환자의 편안함을 향상시킵니다. 또한 정위적 방사선 치료(SBRT)와 정위적 방사선 수술(SRS)의 채택이 증가하고 있으며, 전 세계 주요 종양 센터에서 사이버나이프 시스템의 통합이 추진되고 있습니다.
사이버나이프 시스템의 최신 기술 발전은?
로봇 방사선 수술의 끊임없는 기술 혁신은 사이버나이프의 능력을 크게 향상시켜 치료의 정확성, 효율성, 안전성을 높였습니다. 가장 주목할 만한 발전 중 하나는 AI를 통한 종양 추적 기능을 통합하여 환자의 움직임에 따라 실시간으로 방사선 빔을 조정할 수 있게 되었습니다는 점입니다. 이는 호흡 운동이 표적 정확도에 영향을 미칠 수 있는 폐와 같은 이동성 장기의 종양 치료에 특히 유용합니다.
또 다른 돌파구는 더 높은 선량을 더 짧은 치료시간에 조사하여 치료 횟수를 줄이는 차세대 선형 가속기(선형릭)의 개발입니다. 또한 MRI 유도하 방사선 수술, 적응형 방사선 치료 등 첨단 영상 진단이 사이버나이프 시스템과 통합되어 치료 계획의 정교화와 임상적 성과 향상을 도모하고 있습니다. 또한 클라우드 기반 치료 계획 및 원격 모니터링 기능도 확대되어 종양 전문의가 원격으로 협력하여 치료 프로토콜을 조정할 수 있게 되었습니다.
시장 동향과 헬스케어 정책은 사이버나이프 도입에 어떤 영향을 미치고 있는가?
사이버나이프의 채택은 비침습적 암 치료로의 전환, 환자 중심 치료에 대한 관심 증가, 방사선 수술의 보험 적용 범위 확대 등 진화하는 헬스케어 동향에 의해 형성되고 있습니다. 신흥 시장의 헬스케어 인프라 확대도 사이버나이프의 보급에 기여하고 있으며, 병원들은 증가하는 암 치료 수요에 대응하기 위해 최첨단 종양학 솔루션에 투자하고 있습니다.
FDA, 유럽의약품청(EMA) 등 규제기관은 방사선 치료 시스템의 안전성과 유효성을 보장하기 위해 지속적으로 가이드라인을 업데이트하고 있습니다. 이러한 규제로 인해 사이버나이프 제조업체들은 품질관리를 강화하고, AI를 활용한 안전 메커니즘을 개발하며, 국제 방사선 치료 기준 준수를 향상시켜야 하는 상황에 직면해 있습니다. 또한 사이버나이프의 효능을 지원하는 임상연구가 증가함에 따라 주요 방사선 수술 솔루션으로서의 입지가 강화되고 있습니다.
사이버나이프 시장의 성장 원동력은?
사이버나이프 시장 성장의 원동력은 로봇 방사선 수술의 발전, 암 발병률 증가, 비침습적 치료법에 대한 선호도 증가 등입니다. 더 많은 의료 서비스 프로바이더들이 정밀 방사선 치료의 이점을 인식하게 되면서 선진국과 개발도상국을 막론하고 사이버나이프 시스템에 대한 투자가 확대되고 있습니다.
신경외과, 정형외과, 소아방사선치료에서는 보다 정밀하고 최소침습적인 치료를 위해 사이버나이프가 사용되고 있습니다. 환자 및 종양 전문의들 사이에서 사이버나이프의 인지도가 높아진 것도 시장 성장을 촉진하고 있으며, 특히 치료 결과가 생존율 향상과 부작용 감소를 지속적으로 입증하고 있으며, 시장 성장에 힘을 실어주고 있습니다. 또한 의료 서비스 프로바이더와 방사선 치료 기술 기업 간의 파트너십은 혁신을 촉진하고 접근성을 향상시키며 사이버나이프 치료 프로토콜의 지속적인 발전을 보장합니다.
부문
용도(암용도, 종양 용도, 혈관 기형 용도, 기타 용도); 최종 용도(병원 최종 용도, 외래 환자 시설 최종 용도, 조사·제조 최종 용도)
조사 대상 기업의 예
Apollo Hospitals
Azienda Ospedaliera di Padova
Centre Oscar Lambret
Charite-Universitatsmedizin Berlin
Clinica Universidad de Navarra
CyberKnife Center at Mercy Hospital
CyberKnife Center Munich
CyberKnife Center of Miami
CyberKnife Center of Southern California
Hopital Europeen Georges-Pompidou
Instituto de Radiocirugia CyberKnife IRCA
National Cancer Centre Singapore
Ospedale San Raffaele
Providence Swedish Radiosurgery Center
Samsung Medical Center
Stanford Health Care
Tata Memorial Hospital
The Harley Street Clinic
Universitatsklinikum Heidelberg
University College Hospital London
AI 통합
Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global CyberKnife Market to Reach US$1.7 Billion by 2030
The global market for CyberKnife estimated at US$618.4 Million in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 18.5% over the analysis period 2024-2030. Cancer Application, one of the segments analyzed in the report, is expected to record a 20.0% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Tumor Application segment is estimated at 17.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$168.5 Million While China is Forecast to Grow at 24.5% CAGR
The CyberKnife market in the U.S. is estimated at US$168.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$387.5 Million by the year 2030 trailing a CAGR of 24.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.6% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.8% CAGR.
Global CyberKnife Market - Key Trends & Growth Drivers Summarized
Why Is CyberKnife Gaining Recognition in Precision Radiation Therapy?
CyberKnife, a state-of-the-art robotic radiosurgery system, has revolutionized cancer treatment by offering non-invasive, high-precision radiation therapy. Unlike traditional radiation techniques, CyberKnife utilizes real-time image guidance and robotic technology to target tumors with sub-millimeter accuracy, minimizing damage to surrounding healthy tissues. This has made it an essential tool in treating complex cancers, including brain, prostate, lung, spine, and pancreatic tumors.
The rising global cancer burden has intensified the demand for advanced radiotherapy solutions, with CyberKnife emerging as a preferred alternative for patients seeking pain-free, outpatient-based treatment. Its ability to adapt to patient movement, particularly in lung and prostate cancer cases, enhances treatment efficacy and patient comfort. Additionally, the growing adoption of stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) has propelled the integration of CyberKnife systems in leading oncology centers worldwide.
What Are the Latest Technological Advancements in CyberKnife Systems?
Continuous innovation in robotic radiosurgery has significantly improved CyberKnife’s capabilities, enhancing treatment accuracy, efficiency, and safety. One of the most notable advancements is the integration of AI-driven tumor tracking, allowing real-time adjustments to radiation beams based on patient movement. This is particularly beneficial for treating tumors in mobile organs, such as the lungs, where respiratory motion can affect targeting precision.
Another breakthrough is the development of next-generation linear accelerators, which deliver higher radiation doses in shorter treatment times, reducing the number of sessions required. Additionally, advanced imaging modalities, including MRI-guided radiosurgery and adaptive radiotherapy, are being integrated with CyberKnife systems to refine treatment planning and improve clinical outcomes. Cloud-based treatment planning and remote monitoring capabilities are also expanding, allowing oncologists to collaborate and adjust treatment protocols remotely.
How Are Market Trends and Healthcare Policies Influencing CyberKnife Adoption?
The adoption of CyberKnife is being shaped by evolving healthcare trends, including the shift toward non-invasive cancer treatments, increased focus on patient-centered care, and growing reimbursement coverage for radiosurgery procedures. The expansion of healthcare infrastructure in emerging markets has also contributed to CyberKnife’s adoption, as hospitals invest in cutting-edge oncology solutions to meet rising cancer treatment demands.
Regulatory agencies, including the FDA and the European Medicines Agency (EMA), are continuously updating guidelines to ensure the safety and efficacy of radiation therapy systems. These regulations have driven CyberKnife manufacturers to enhance quality control, develop AI-driven safety mechanisms, and improve compliance with international radiation therapy standards. Additionally, the rising number of clinical studies supporting CyberKnife’s efficacy is strengthening its position as a leading radiosurgery solution.
What Is Driving the Growth of the CyberKnife Market?
The growth in the CyberKnife market is driven by advancements in robotic radiosurgery, increasing cancer incidence rates, and the growing preference for non-invasive treatment modalities. As more healthcare providers recognize the benefits of precision radiation therapy, investments in CyberKnife systems are expanding across developed and developing regions.
End-use expansion is another key factor, with neurosurgery, orthopedic oncology, and pediatric radiation therapy incorporating CyberKnife for more precise, minimally invasive treatments. The rising awareness of CyberKnife among patients and oncologists is also fueling market growth, particularly as treatment outcomes continue to demonstrate improved survival rates and reduced side effects. Additionally, partnerships between healthcare providers and radiotherapy technology firms are fostering innovation, enhancing accessibility, and ensuring continued advancements in CyberKnife treatment protocols.
SCOPE OF STUDY:
The report analyzes the CyberKnife market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Application (Cancer Application, Tumor Application, Vascular Malformation Application, Other Applications); End-Use (Hospitals End-Use, Outpatient Facilities End-Use, Research and Manufacturing End-Use)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 42 Featured) -
Apollo Hospitals
Azienda Ospedaliera di Padova
Centre Oscar Lambret
Charite - Universitatsmedizin Berlin
Clinica Universidad de Navarra
CyberKnife Center at Mercy Hospital
CyberKnife Center Munich
CyberKnife Center of Miami
CyberKnife Center of Southern California
Hopital Europeen Georges-Pompidou
Instituto de Radiocirugia CyberKnife IRCA
National Cancer Centre Singapore
Ospedale San Raffaele
Providence Swedish Radiosurgery Center
Samsung Medical Center
Stanford Health Care
Tata Memorial Hospital
The Harley Street Clinic
Universitatsklinikum Heidelberg
University College Hospital London
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
CyberKnife - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Cancer Globally Fuels Adoption of Non-Invasive Radiosurgical Solutions Like CyberKnife
Advancements in Real-Time Tumor Tracking and Adaptive Radiotherapy Enhance Clinical Outcomes
OEM Innovation in Image-Guided Robotic Systems Propels CyberKnife Over Conventional Linac Systems
Increased Deployment in Private Cancer Care Chains and Specialty Oncology Centers Drives Market Expansion
FDA and CE Mark Approvals for Expanded Indications Accelerate Global CyberKnife Adoption
Integration With Treatment Planning and AI-Powered Dosimetry Systems Improves Accuracy and Efficiency
Growing Use in Intracranial, Spinal, Lung, and Prostate Tumors Broadens Application Scope
Rising Referrals From Neurosurgeons and Radiation Oncologists Boost Clinical Awareness and Volume
OEM Expansion Into Emerging Markets Supports Access to Robotic Radiosurgery Technology
Favorable Reimbursement for Radiosurgery in Developed Markets Enhances Adoption Rates
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World CyberKnife Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for CyberKnife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Tumor Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Tumor Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Tumor Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Vascular Malformation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Vascular Malformation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Vascular Malformation Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Outpatient Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Outpatient Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Outpatient Facilities End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Research & Manufacturing End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Research & Manufacturing End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Research & Manufacturing End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 27: USA Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 28: USA 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 31: USA 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 34: Canada 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 36: Canada Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 37: Canada 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
JAPAN
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 40: Japan 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: Japan Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 43: Japan 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
CHINA
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 44: China Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: China Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 46: China 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: China Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 49: China 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
EUROPE
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 51: Europe Historic Review for CyberKnife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 52: Europe 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 55: Europe 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 58: Europe 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
FRANCE
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 59: France Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: France Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 61: France 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: France Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 64: France 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
GERMANY
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: Germany Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 67: Germany 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 70: Germany 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: Italy Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 73: Italy 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 76: Italy 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
UNITED KINGDOM
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: UK Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 79: UK 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: UK Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 82: UK 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
SPAIN
TABLE 83: Spain Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Spain Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 85: Spain 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 86: Spain Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: Spain Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 88: Spain 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
RUSSIA
TABLE 89: Russia Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: Russia Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 91: Russia 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 92: Russia Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Russia Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 94: Russia 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 97: Rest of Europe 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 100: Rest of Europe 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
ASIA-PACIFIC
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for CyberKnife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 103: Asia-Pacific 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 106: Asia-Pacific 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 109: Asia-Pacific 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
AUSTRALIA
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 110: Australia Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Australia Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 112: Australia 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 113: Australia Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: Australia Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 115: Australia 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
INDIA
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 116: India Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: India Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 118: India 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 119: India Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: India Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 121: India 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 122: South Korea Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 124: South Korea 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 125: South Korea Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 127: South Korea 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 130: Rest of Asia-Pacific 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 133: Rest of Asia-Pacific 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
LATIN AMERICA
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 134: Latin America Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for CyberKnife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 136: Latin America 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 137: Latin America Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 139: Latin America 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 142: Latin America 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 143: Argentina Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Argentina Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 145: Argentina 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 146: Argentina Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 148: Argentina 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
BRAZIL
TABLE 149: Brazil Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: Brazil Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 151: Brazil 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 152: Brazil Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 154: Brazil 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
MEXICO
TABLE 155: Mexico Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Mexico Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 157: Mexico 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 158: Mexico Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 160: Mexico 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Rest of Latin America Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 163: Rest of Latin America 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 166: Rest of Latin America 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
MIDDLE EAST
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 167: Middle East Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for CyberKnife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 169: Middle East 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 170: Middle East Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 172: Middle East 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 175: Middle East 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
IRAN
TABLE 176: Iran Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: Iran Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 178: Iran 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 179: Iran Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: Iran Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 181: Iran 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
ISRAEL
TABLE 182: Israel Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: Israel Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 184: Israel 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 185: Israel Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: Israel Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 187: Israel 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Saudi Arabia Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 190: Saudi Arabia 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 193: Saudi Arabia 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 194: UAE Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: UAE Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 196: UAE 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 197: UAE Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 198: UAE Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 199: UAE 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Rest of Middle East Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 202: Rest of Middle East 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 205: Rest of Middle East 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
AFRICA
CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 206: Africa Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Africa Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 208: Africa 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
TABLE 209: Africa Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 210: Africa Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 211: Africa 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030